507 results on '"Keyvani, Kathy"'
Search Results
2. Cranioencephalic functional lymphoid units in glioblastoma
3. The multiple roles of nerve biopsy in the diagnosis and prognosis of suspected immune neuropathies
4. Moyamoya disease in Southeast Asians: genetic and autopsy data, new cases, systematic review, and meta-analysis of all patients from the literature
5. Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma
6. KDM5B predicts temozolomide-resistant subclones in glioblastoma
7. ATRT–SHH comprises three molecular subgroups with characteristic clinical and histopathological features and prognostic significance
8. Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography
9. The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue, 68Ga-FAPI-46 PET Data, and Survival Data.
10. Is kallikrein-8 a blood biomarker for detecting amnestic mild cognitive impairment? Results of the population-based Heinz Nixdorf Recall study
11. Compromised Hippocampal Neuroplasticity in the Interferon-α and Toll-like Receptor-3 Activation-Induced Mouse Depression Model
12. Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric 18F-FET PET-MRI and MR Fingerprinting
13. Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma
14. Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults
15. NIMG-82. FET PET SENSITIVITY IN PRIMARY BRAIN TUMORS ACCORDING TO CNS WHO 2021: VALUE AND PITFALLS IN PRESURGICAL IMPLEMENTATION
16. NIMG-34. TEMPORAL MUSCLE THICKNESS AS A PROGNOSTIC MARKER IN A REAL-LIFE COHORT OF NEWLY DIAGNOSED MGMT PROMOTER METHYLATED GLIOBLASTOMA PATIENTS: A MULTICENTRIC IMAGING ANALYSIS
17. Blood Kallikrein-8 and Non-Amnestic Mild Cognitive Impairment: An Exploratory Study
18. Aβ dimers induce behavioral and neurochemical deficits of relevance to early Alzheimer's disease
19. Histopathology of Moyamoya angiopathy in a European patient
20. Regorafenib in patients with recurrent high-grade astrocytoma
21. Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma
22. Frequent BRAF Gain in Low‐Grade Diffuse Gliomas with 1p/19q Loss
23. Feasibility and Tolerability of Trofosfamide and Etoposide in Progressive Glioblastoma
24. Association of primary central nervous system vasculitis with the presence of specific human leucocyte antigen gene variant
25. The predominant expression of cancer stem cell marker ALDH1A3 in tumor infiltrative area is associated with shorter overall survival of human glioblastoma
26. Location of Recurrences after Trimodality Treatment for Glioblastoma with Respect to the Delivered Radiation Dose Distribution and Its Influence on Prognosis
27. Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
28. A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
29. Genetic and functional analyses of CTBP2in anorexia nervosa and body weight regulation
30. Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma
31. Hybrid 11C-MET PET/MRI Combined With “Machine Learning” in Glioma Diagnosis According to the Revised Glioma WHO Classification 2016
32. Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report
33. CTNI-34. PRECISION NEURO-ONCOLOGY - A PILOT ANALYSIS OF PERSONALIZED TREATMENT IN RECURRENT GLIOMA
34. CTNI-43. COMBINATION OF TROFOSFAMIDE PLUS ETOPOSIDE IN RECURRENT ADULT-TYPE DIFFUSE GLIOMAS
35. CTNI-18. FIRST MULTICENTRIC REAL-LIFE EXPERIENCE WITH THE COMBINATION OF CCNU AND TEMOZOLOMIDE IN NEWLY DIAGNOSED MGMT PROMOTER METHYLATED IDH WILDTYPE GLIOBLASTOMA
36. TMIC-66. FIBROBLAST ACTIVATION PROTEIN: TISSUE EXPRESSION, POSITRON-EMISSION TOMOGRAPHY UPTAKE AND ITS PROGNOSTIC SIGNIFICANCE IN GLIOSARCOMAS AND GLIOBLASTOMAS
37. A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
38. Predictive chromosomal clusters of synchronous and metachronous brain metastases in clear cell renal cell carcinoma
39. Cerebral amyloidoma is characterized by B‐cell clonality and a stable clinical course
40. Activation of multiple angiogenic signaling pathways in hemangiopericytoma
41. The Multi-target Effects of CNI-1493: Convergence of Antiamylodogenic and Antiinflammatory Properties in Animal Models of Alzheimer’s Disease
42. Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma
43. EphB4 forward signalling mediates angiogenesis caused by CCM3/PDCD10‐ablation
44. Study of angiogenic signaling pathways in hemangioblastoma
45. Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis
46. Precision neuro-oncology - a pilot analysis of personalized treatment in recurrent primary brain cancer
47. First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
48. Amyloid-β dimers in the absence of plaque pathology impair learning and synaptic plasticity
49. Report of a fulminant anti‐ pan‐neurofascin ‐associated neuropathy responsive to rituximab and bortezomib
50. Analysis of Varicella-Zoster Virus in Temporal Arteries Biopsy Positive and Negative for Giant Cell Arteritis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.